Compare SHOO & GPCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SHOO | GPCR |
|---|---|---|
| Founded | 1990 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Shoe Manufacturing | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7B | 2.8B |
| IPO Year | 1996 | 2023 |
| Metric | SHOO | GPCR |
|---|---|---|
| Price | $39.07 | $38.21 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 12 |
| Target Price | $42.14 | ★ $103.17 |
| AVG Volume (30 Days) | ★ 1.0M | 815.9K |
| Earning Date | 05-06-2026 | 05-08-2026 |
| Dividend Yield | ★ 2.27% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.00 | N/A |
| Revenue | ★ $2,534,109,000.00 | N/A |
| Revenue This Year | $12.39 | N/A |
| Revenue Next Year | $5.90 | N/A |
| P/E Ratio | $39.03 | ★ N/A |
| Revenue Growth | ★ 11.00 | N/A |
| 52 Week Low | $22.26 | $15.80 |
| 52 Week High | $46.88 | $94.90 |
| Indicator | SHOO | GPCR |
|---|---|---|
| Relative Strength Index (RSI) | 55.68 | 25.90 |
| Support Level | $36.08 | $30.82 |
| Resistance Level | $40.25 | $40.29 |
| Average True Range (ATR) | 1.56 | 2.44 |
| MACD | 0.09 | -0.38 |
| Stochastic Oscillator | 58.79 | 2.51 |
Steven Madden Ltd and its subsidiaries design, source, and market branded and private label footwear, accessories, and apparel. Its offerings include contemporary styles and core products, known for design creativity, trend-right offerings, high quality, and accessible price points. It operates through four segments: Wholesale Footwear, which generates maximum revenue and sells footwear globally; Wholesale Accessories/Apparel, which sells handbags and apparel through wholesale channels; Direct-to-Consumer, which sells footwear, handbags, apparel, and accessories through stores, outlets, e-commerce, and concessions; and Licensing, which licenses Steve Madden, Betsey Johnson, and Kurt Geiger trademarks, with the Company generating the majority of its revenue from the USA.
Structure Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel oral small-molecule therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its differentiated technology platform leverages both structure-based drug discovery and expertise in computational chemistry to discover and develop small molecule therapeutics against G-protein coupled receptors (GPCRs). The group operates and manages its business as one reportable and operating segment, which is the business of research and development of medicines that target chronic diseases with unmet medical needs.